特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 今天我们讲讲 山东大学 2023年 获批教育部重点实验室 的 科技考古实验室以及他所在的考 古实验室群 。 山 东 大 学 文 化 遗 产 研 究 院 现 拥 有 实 验 设 施 6700 平 方 米 ， 设 有 人 类 演 化 、 植 物 考 古 、 动 物 考 古 、 地 学 考 古 、 体 质 人 类 学 、 同 位 素 考 古 、 古 DNA 分 析 、 陶 瓷 器 分 析 、 玉 石 器 分 析 、 冶 金 考 古、考古地磁测年（筹）、文物保护与修复和室内考古等15个实验室，拥有实验设备1300余 台（套），设备总值1000余万元。 科技考古实验室群位于2017年建成的山东大学博物馆大楼中，面积达5000多平方米。 目 前 已建成人类演化、植物考古、动物考古、沉积学、体质人类学、陶瓷考古、石器考古、冶金考 古、稳定同位素、海洋考古、文物保护修复、模拟数字考古和唐仲英基金室内考古发掘与保护 等1 6个考古实验室，是 国内空间最广、规模最大、门类最全、结构最完整的考古实验室群 。 研究 ...

Core Viewpoint - The total procurement application amount is approximately 1.53 billion yuan, primarily for instruments and equipment, accounting for over 99% (about 1.52 billion yuan), with a small portion involving books and electric motors [1][4]. Summary by Sections Procurement Overview - The procurement involves 21 universities in Liaoning Province, with a focus on importing products as per the expert evaluation results [2][8]. - The procurement is aimed at enhancing the capabilities of educational institutions through advanced equipment [8]. Detailed Procurement List - A comprehensive list of proposed purchases includes various high-tech instruments such as high-throughput imaging systems, fluorescence microscopes, and PCR instruments, with individual prices ranging from 6 million to 2.1 billion yuan [4][5]. - Notable purchases include: - High-throughput tissue imaging analysis system at 1.6 million yuan [4]. - High-resolution integrated intelligent imaging system at 1.3 million yuan [5]. - High-throughput fully automated biological intelligent analysis system at 21 million yuan [5]. University-Specific Procurement Amounts - The procurement amounts for specific universities are as follows: - Shenyang Agricultural University: 299.88 million yuan for 554 units [6]. - China Medical University: 238.72 million yuan for 107 units [7]. - Dalian Medical University: 107.81 million yuan for 60 units [6][7]. Policy Guidelines - The procurement process emphasizes supporting national enterprises' independent innovation and prioritizing products that offer technology transfer and training services [8]. - For major technological equipment and scientific instruments restricted from import, approvals from relevant provincial departments are required [8].

Core Viewpoint - Zhejiang University of Technology has announced a procurement intention for the second phase of the Peak Discipline Equipment Update Project, with a total budget of 97.87 million yuan [3]. Procurement Overview - The procurement involves various advanced instruments including online gas mass spectrometers, near-infrared fluorescence spectrometers, in-situ Fourier infrared spectrometers, desktop scanning electron microscopes, and flow cytometers [3]. - The expected procurement time is set for July 2025 [3]. Detailed Instrument Specifications - **Subcutaneous Fingerprint Acquisition Sweeping OCT System**: Budget of 9.16 million yuan, designed for high-speed and high-bandwidth data acquisition [5]. - **Four-legged Robot from Yushu Technology**: Budget of 550,000 yuan, aimed at high-precision 3D spatial data acquisition [5]. - **General High-Precision Pose Measurement Platform**: Budget of 980,000 yuan, supporting various navigation signals for multiple disciplines [5]. - **Heterogeneous Multi-Machine Collaborative Detection Platform**: Budget of 580,000 yuan, facilitating experiments in intelligent perception and control [5]. - **Intelligent Robot Drive Control Development Testing Platform**: Budget of 900,000 yuan, for developing control systems and algorithms [6]. - **Micro-focus Industrial XCT Machine**: Budget of 3.5 million yuan, for material characterization [6]. - **Enzyme Labeling Instrument**: Budget of 500,000 yuan, crucial for environmental health research [6]. - **High-Performance Micro-Pore Structure Magnetic Resonance Characterization Instrument**: Budget of 700,000 yuan, for micro-structural testing [6]. Additional Instrument Details - **Explosion-proof Air Conditioning Units**: Budget of 620,000 yuan, ensuring safety in chemical reagent storage [7]. - **Mobile Integrated V2X Perception Station**: Budget of 600,000 yuan, for intelligent traffic perception research [7]. - **Nanometrics Ultra-Wideband Seismometer**: Budget of 2 million yuan, for long-term solid tide and gravity monitoring [7]. - **Laser Ablation System**: Budget of 800,000 yuan, for research in medical AI and brain-machine intelligence [8]. - **High-Performance Liquid Chromatography Mass Spectrometer**: Budget of 950,000 yuan, for wastewater analysis [11]. - **Synthetic Biology Intelligent Analysis System**: Budget of 2 million yuan, for monitoring fermentation processes [15]. Strategic Importance - The procurement aligns with the university's focus on advancing research capabilities across various strategic fields, including environmental technology, intelligent control, and artificial intelligence [5][6][7].

Group 1 - The total procurement application amount is approximately 1.53 billion yuan, primarily for instruments and equipment, accounting for over 99% (about 1.52 billion yuan), with a small portion related to books and electric motors [1] Group 2 - The fourth Micro Course Competition has officially started in April, with participation information received from 23 institutions [6]

Core Viewpoint - The first loss compensation insurance for shared scientific research instruments has been implemented in Suzhou, addressing long-standing issues related to equipment damage liability, thereby encouraging the sharing of high-end research instruments [2][3]. Group 1: Insurance Implementation - The insurance provides over 4 million yuan in risk coverage for large shared scientific research equipment at Suzhou University of Science and Technology [2]. - The insurance scheme integrates a "sharing economy + technology insurance" model, covering risks from design defects, installation errors, and operational mistakes [3]. Group 2: Impact on Research Institutions - The Suzhou University of Science and Technology has been providing technical support services for medical device and raw material R&D, owning high-end research instruments valued at over 10 million yuan [2]. - The insurance alleviates concerns about equipment damage, enabling the institution to fully utilize high-end equipment for comprehensive testing services [3]. Group 3: Future Directions - The municipal science and technology department plans to collaborate with instrument management departments, universities, and maintenance units to promote the use of more scientific instruments outside laboratories [3].

导读： 为持续激发民间投资活力，国家发展改革委进一步加大工作力度，近日组织集中向民间资本新推 介项目3200余个、涉及项目总投资超3万亿元。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 2023年9月，国家发展改革委搭建了"全国向民间资本推介项目平台"，旨在推介各地梳理报 送的基础设施等领域优质项目，持续吸引民间资本。全国投资项目在线审批监管平台数据显 示，截止今年6月23日，全国正在向民间资本推介项目11751个、总投资额10.15万亿。 按照党中央、国务院决策部署，为持续激发民间投资活力，国家发展改革委进一步加大工作力 度，近日组织 集中向民间资本新推介 项目3200余个 、涉及项目总投资 超3万亿元 。 本批项目 聚焦交通运输、能源、水利、新型基础设施、城市基础设施、环保、仓储物流、制造 业等重点领域 ，依托"全国向民间资本推介项目平台"向社会公开推介。同时，组织各地建立 健全向民间资本推介项目专项工作协调机制，推动更多民间投资参与项目建设，加强跟踪协调 和对接服务，强化用地用海、环评等要素和融资支持，推动项目尽快落地实施。 下 ...

Core Viewpoint - The article highlights the market capitalization changes of major domestic life science instrument manufacturers in China for 2025, indicating a mixed performance with significant growth for some companies and declines for others due to policy impacts and market dynamics [1][2]. Market Capitalization Summary - The top five companies by market capitalization in 2025 are Mindray Medical, Sunny Optical, BGI Genomics, Antu Bio, and Haier Biomedical [2]. - A total of 10 companies experienced growth in market capitalization compared to 2024, with Zhongke Meiling leading at a growth rate of +130.44% [2]. - Four companies saw a decline in market capitalization, with Antu Bio experiencing the most significant drop at -26.70% [2]. Policy Impact Analysis - The medical anti-corruption and centralized procurement policies have negatively affected the revenue of several companies, leading to a 35% decrease in equipment bidding volume in tertiary hospitals [3]. - Mindray Medical, despite being an industry leader, faced a revenue growth drop from 25% to 9% due to procurement delays and budget constraints from DRG payment reforms [3]. - Antu Bio's revenue decreased by 18% in 2024 due to the impact of centralized procurement on the prices of chemical luminescence reagents [4]. Growth Drivers - Companies are shifting towards technology innovation as traditional high-margin models and bundled sales strategies become less viable under centralized procurement [5]. - Domestic microscope manufacturers have seen significant market capitalization growth, with Sunny Optical (+47.04%), Yongxin Optical (+27.11%), and Motic (+69.22%) benefiting from increased demand and technological advancements [7]. - Zhongke Meiling achieved a market share increase from 3% to 8% by overcoming technical barriers in ultra-low temperature freezing equipment [8]. International Expansion and Market Strategy - Companies are increasingly focusing on international markets to seek new growth opportunities, with Mindray Medical expanding its factory in New Jersey as part of its international strategy [8]. - BGI Genomics and Motic are also pursuing CE/FDA certifications to enter European and American markets, indicating a shift from domestic competition to global opportunities [8].

Core Viewpoint - The article emphasizes the importance of plasmid extraction in the life sciences industry, highlighting the need to understand the challenges faced by professionals in this area [1]. Group 1: Survey Details - A survey is being conducted to gather insights from life science professionals regarding their experiences with plasmid extraction [2]. - The survey is open from June 20 to July 6, with various prizes available for participants, including 50 Xiaomi backpacks, 50 stylish umbrellas, 10 Xiaomi Bluetooth speakers, and 3 Apple AirPods Max valued at 3,999 yuan each [2]. Group 2: Participation and Rewards - Participants can join the survey by scanning a QR code or clicking on a link provided at the end of the article, which takes approximately 30 seconds to complete [4]. - After the survey closes, the organizers will verify the responses and select winners for the prizes [5]. - The list of winners will be announced in an article published on July 18 on the "Instrument Information Network" public account [6].

Core Viewpoint - The FDA has announced an immediate review of clinical trials involving the transfer of live human cells from American citizens to laboratories in China and other "hostile countries" for genetic engineering, indicating a shift towards stricter biotechnology restrictions against China [4][5]. Group 1 - The FDA's review is prompted by concerns that international transfers and genetic engineering operations may occur without patient knowledge or consent, potentially leading to the misuse of sensitive genetic data by foreign governments, including those of hostile nations [5]. - The Biden administration's data security rules set in December 2024 included export controls but allowed a "comprehensive exemption" for clinical trial biological samples, creating regulatory loopholes that permitted participation from Chinese-funded enterprises [5]. - FDA Commissioner Marty Makary emphasized the importance of the integrity of the biomedical research system and stated that actions are being taken to protect patients, rebuild public trust, and defend America's biomedical leadership [5].

Core Viewpoint - Illumina announced the acquisition of SomaLogic for $350 million in cash, with potential performance-based milestones and royalties totaling up to $75 million, aimed at strengthening its position in the growing proteomics market and enhancing its multi-omics strategy [1][2]. Group 1: Acquisition Details - The acquisition includes SomaLogic's aptamer-based affinity proteomics platform, which will enhance Illumina's presence in the high-growth proteomics sector [2]. - Illumina expects the business to achieve profitability based on non-GAAP operating income by 2027, with non-GAAP operating margins aligning with Illumina by 2028 [2]. - The transaction is subject to customary closing conditions, including regulatory approvals, with completion anticipated in the first half of 2026 [2]. Group 2: Strategic Implications - Illumina's CEO emphasized that the acquisition will enhance the value of the NovaSeq X product and unlock greater capabilities in the future [1]. - The collaboration between Illumina and SomaLogic has been ongoing for over three years, improving service capabilities and accelerating the technological roadmap for advanced biomarker detection and disease analysis [1]. - The integration of SomaLogic's technology is expected to apply the scalability of NGS (Next-Generation Sequencing) to proteomics, maintaining an open and empowering NGS platform [1]. Group 3: Company Background - SomaLogic employs approximately 250 staff globally, with operations in Boulder, Colorado, including CLIA and CAP certified laboratories [2]. - Prior to the acquisition, Illumina and SomaLogic had a joint development agreement established in December 2021 to implement SomaScan proteomics detection on Illumina's NGS platform [3].